Over Seven Pharma Companies Secure Funding This Week, Simcere Raises RMB 1.419 Billion; Multiple Firms File IPO Prospectuses

　　【Pharmaceutical Network Industry DynamicsSince this week, there has been continuous news of investment and financing in the pharmaceuticals industry, with at least seven companies completing funding rounds, including iRegene, Shanghai Yinuo Pharmaceutical, Simcere, Enitiatebio, and Tonglu Technology. In terms of the amount of financing, some have even exceeded 1 billion yuan.
 

　　iRegene: Completed Series B Financing
 

News on September 4: Recently, iRegene, a company specializing in universal chemically induced cell therapy drugs, announced the completion of its B+ round of financing. This round of financing was jointly completed by Northern Light Venture Capital, Vision Capital, and Yuanxi Haihe, among other institutions. The funds from this round of financing will be used to accelerate the clinical advancement of the company's Parkinson's disease treatment products NouvNeu001/NouvNeu003 and ophthalmic treatment product NouvSight001 both in China and internationally. Additionally, it will strengthen the company’s early R&D and clinical team building and expedite the company’s industrialization capabilities.
 

　　Borui Pharmaceutical: Secures RMB 500 Million in Strategic Investment
 

On September 3, BrightGene Bio-Medical Technology announced the completion of a new round of strategic investment. This investment aims to strengthen BrightGene's capabilities in innovative drug research and development as well as complexActive Pharmaceutical IngredientsAnd the core competitiveness in the field of formulation production.
 

The completion of this strategic investment will further advance Bori Pharma's progress in the field of innovative drug research and development, and enhance its market position in the production of complex active pharmaceutical ingredients (APIs) and formulations. Bori Pharma stated that it would utilize the investment funds to strengthen the R&D team, optimize production processes, and expand both domestic and international markets, providing high-quality pharmaceutical products to more patients.
 

　　Shanghai Yinuo Pharmaceutical Co., Ltd.: Completes Series C Financing
 

September 2nd Update: Recently, Shanghai Yinuo Pharmaceutical Co., Ltd. has completed its Series C financing round, with participation from investors including Kangcheng Investment and Zhangke Lingyi. The funds from this round will primarily be used to advance clinical trials, support early-stage R&D for pipeline reserves, and build up the R&D team.
 

　　Simcere: Secures RMB 1.419 Billion Strategic Investment
 

On September 2, Simcere announced the completion of a new round of strategic investment. This investment aims to strengthen Simcere's R&D capabilities, expand production scale, and accelerate the process of new drug launches. It is reported that this round of strategic investment will help Simcere further enhance its competitiveness in the pharmaceuticals industry and promote the company’s progress towards becoming an international pharmaceutical enterprise. The company stated that it will continue to increase R&D investment, optimize its product structure, and provide patients with more high-quality medicines in the future.
 

Data shows that Simcere is a company focused on pharmaceutical production, with products covering multiple disease treatment areas including anti-tumor, cardiovascular and cerebrovascular, anti-infective, and rheumatology immunology. The company's main products include Recombinant Human Endostatin Injection, Fluorouracil Implant, and Levamlodipine Besylate Tablets.
 

Enitiatebio: Completes RMB 200 Million Series B Financing
 

On September 2, it was reported that Enitiatebio recently announced the completion of a nearly 200 million yuan Series B financing round. This round was led by Fuzhe Fund, with participation from Hony Capital, Hangzhou Industrial Investment Group, and two professional investors. Enitiatebio focuses on diseases with significant unmet clinical needs, such as atopic dermatitis, psoriasis, and vitiligo, and has already initiated more than ten clinical studies.
 

　Tonglu Technology: Completes A+ Round Financing
 

On September 2, Tonglü Technology announced the completion of its A+ round of financing invested by Ruiqian Capital. This round of financing will be mainly used to accelerate Tonglü Technology's progress in vascular interventional surgery.RobotResearch and development in the field and the promotion of intelligent surgical solutions.
 

Data shows that Tonglü Technology is a high-tech enterprise focusing on the research and development of vascular interventional surgical robots. The company is committed to meeting the developmental needs of minimally invasive vascular interventional surgery by deeply engaging in the independent research and development of next-generation surgical robots and cutting-edge studies in the information field. Tonglü Technology has innovatively developed a new type of vascular interventional surgical robot plus treatment platform, aiming to provide intelligent surgical solutions to medical institutions, enhancing the precision and efficiency of surgeries.
 

　Hertz Life: Secures Strategic Investment
 

On September 1, Hertz Life, which focuses on Virus-Like Particles (VLPs) vaccine research and development, announced the completion of a strategic investment. This round of financing will mainly be used for the company's VLPs vaccine R&D and industrialization progress. The company stated that it will use the funds to accelerate the clinical development and market promotion of its core products, while expanding more application scenarios for VLPs vaccines, contributing more innovative strength to the global animal health field.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.